Abstract: The present invention is directed to PVRIG polypeptides and their uses.
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
February 4, 2020
Assignee:
Compugen, Ltd.
Inventors:
Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.
Type:
Grant
Filed:
May 11, 2016
Date of Patent:
January 28, 2020
Assignee:
PD-1 Acquisition Group, LLC
Inventors:
Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
Type:
Grant
Filed:
September 10, 2016
Date of Patent:
December 31, 2019
Assignee:
Yeda Research and Development Co. Ltd
Inventors:
Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Abstract: The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Grant
Filed:
July 13, 2016
Date of Patent:
December 24, 2019
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Kimberly Ann Tipton, James William West, Chanty Mariategue Chan
Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
Type:
Grant
Filed:
December 18, 2017
Date of Patent:
December 10, 2019
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides, compositions, and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
December 10, 2019
Assignee:
Spring BioScience Corporation
Inventors:
Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
December 3, 2019
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Type:
Grant
Filed:
March 9, 2017
Date of Patent:
November 26, 2019
Assignee:
Merck Patent GmbH
Inventors:
Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Type:
Grant
Filed:
October 19, 2018
Date of Patent:
November 19, 2019
Assignees:
AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
Inventors:
Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
Abstract: Provided are anti-PD-1 antibodies or fragments thereof. In various example, the antibodies or fragments thereof includes a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
November 5, 2019
Assignee:
TAYU HUAXIA BIOTECH MEDICAL GROUP CO., LTD.
Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Type:
Grant
Filed:
April 30, 2019
Date of Patent:
October 22, 2019
Assignees:
AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
Inventors:
Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Baek Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type:
Grant
Filed:
October 7, 2016
Date of Patent:
October 15, 2019
Assignees:
ONO PHARMACEUTICAL CO., LTD., E.R. SQUIBB & SONS, L.L.C.
Inventors:
Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
Type:
Grant
Filed:
September 28, 2016
Date of Patent:
October 1, 2019
Assignee:
Celgene Corporation
Inventors:
Brydon Bennett, Philip Paul Chamberlain, Kandasamy Hariharan, Pilgrim Jackson, Marilyn Kehry, Roli Khattri, Monica Leung, Lisa Morrison, Jeonghoon Sun, Sanaa Torres, Henry H. Chan
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
September 24, 2019
Assignee:
AMGEN INC.
Inventors:
Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Type:
Grant
Filed:
September 7, 2016
Date of Patent:
September 24, 2019
Assignee:
AMGEN INC.
Inventors:
Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick Jacobsen, Wayne Tsuji
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
September 3, 2019
Assignee:
Bristol-Myers Squibb Company
Inventors:
Glen Eugene Mikesell, Han Chang, Robert James Peach
Abstract: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
September 3, 2019
Assignee:
MEDIMMUNE LIMITED
Inventors:
Christophe Queva, Michelle Morrow, Scott Hammond, Marat Alimzhanov, John Babcock, Ian Nevin Foltz, Jaspal Singh Kang, Laura Sekirov, Melanie Boyle, Matthieu Chodorge, Ross A. Stewart, Kathleen Ann Mulgrew
Abstract: The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Type:
Grant
Filed:
August 30, 2016
Date of Patent:
August 6, 2019
Assignees:
Emory University, Dana-Farber Cancer Institute, Inc., Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
Inventors:
Gordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry